Skip to main content

Damme Laura's Form 4 filing

TransMedics Group, Inc. (TMDX) · filed Dec 16, 2022

Accession no.
0000899243-22-038829
Filed
Dec 16, 2022
Trade date
Dec 14-15, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 6 non-derivative transactions and 3 derivative transactions. Open-market sales total $665.7K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Damme LauraCIK 0001784433Officer (VP, Clinical Affairs)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 14, 2022Common StockMOption exerciseAcquired+5,947$38.46+$228,721.625,947Direct
Dec 14, 2022Common StockSSaleDisposed−5,947$62.43F1−$371,271.210Direct
Dec 15, 2022Common StockMOption exerciseAcquired+250$38.46+$9,615250Direct
Dec 15, 2022Common StockSSaleDisposed−250$60.02F2−$15,0050Direct
Dec 15, 2022Common StockMOption exerciseAcquired+4,740$38.46+$182,300.44,740Direct
Dec 15, 2022Common StockSSaleDisposed−4,740$58.96F3−$279,470.40Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 14, 2022Common StockMOption exerciseDisposed−5,947$0.00$019,053Direct
Dec 15, 2022Common StockMOption exerciseDisposed−250$0.00$018,803Direct
Dec 15, 2022Common StockMOption exerciseDisposed−4,740$0.00$014,063Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $62.00 to $62.91, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Referenced by the price of 1 transaction in Table I.

F2

The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $60.00 to $60.35, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Referenced by the price of 1 transaction in Table I.

F3

The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $58.92 to $59.32, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)